Completing the Part B & B Supplemental Program Terms Report PTR
Review of what RWHAP Part B and Part B Supplemental recipients need to know to submit their 2018 Program Terms Reports (PTR).
Resource updated 06/30/2024
Review of what RWHAP Part B and Part B Supplemental recipients need to know to submit their 2018 Program Terms Reports (PTR).
Resource updated 06/30/2024
Los clientes elegibles para un Período de Inscripción Especial (SEP, por sus siglas en inglés) pueden inscribirse en un nuevo plan del Mercado de Seguros Médicos. O, si ya estaban inscriptos en un plan del Mercado de Seguros Médicos, pueden cambiar de plan fuera del periodo estándar de Inscripción Abierta.
El SEP es provocado por eventos de la vida, tales como:
Resource updated 02/15/2024
Kliyan yo ki elijib pou yon Peryòd Enskripsyon Espesyal (Special Enrollment Period, SEP) kapab enskri nan yon nouvo plan asirans sante Marketplace. Oubyen, si yo enskri deja nan yon plan Marketplace, yo kapab chanje plan yo andeyò peryòd Enskripsyon Lib estanda a.
SEP yo deklanche akòz evènman enpòtan nan lavi, tankou:
Resource updated 02/15/2024
Resources for tax filing for individuals with health coverage through the Marketplace and select states with individual mandates to maintain coverage.
Resource updated 01/22/2024
Interactive module on financial help is available for consumers who get health coverage through the Health Insurance Marketplace.
Resource updated 01/25/2024
Online portal for grantees of record to report on deliverables identified in their grant award.
Resource updated 07/17/2024
Overview of Medicare eligibility and coverage for RWHAP clients and other people with HIV.
Resource updated 09/25/2023
Overview of Medicare prescription drug coverage for RWHAP clients and other people with HIV.
Resource updated 11/02/2023
Overview of Medicare eligibility and coverage for RWHAP clients and other people with HIV.
Resource updated 09/19/2023
Resource updated 10/04/2023
Open Enrollment (OE) for 2024 Marketplace health coverage will begin on November 1, 2023 and will run through January 15, 2024 for all states that use HealthCare.gov.
Resource updated 10/23/2023
Resource updated 09/17/2021
Resource updated 08/28/2023
Resource updated 03/15/2023
Rapid has developed into a core feature of the Dorothy Mann Center HIV care continuum, assuring immediate linkage to expert HIV services, immediate initiation of therapy, and rapid viral suppression. Benefits are present for youth prevention services. Rapid access models are feasible and beneficial for youth HIV care and prevention.
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
A clinic-based substance abuse screening and treatment program is described. Using the Screening, Brief Intervention, and Referral to Treatment model, this provides annual proactive screening of alcohol/drug use, with a brief provider response and a follow-up motivational interviewing brief intervention, with treatment provided by an embedded provider.
Resource (Conference Presentation) updated 09/14/2023
Oklahoma has been classified by the Department of Health and Human Services as one of the seven states with a high rural HIV burden. Test-and-treat protocols are feasible within high-volume HIV clinics which serve rural and underserved communities to minimize the time to the first appointment to decrease time to viral load suppression.
Resource (Conference Presentation) updated 09/14/2023
The Marketplace Open Enrollment period lasts only six weeks in most states, and RWHAP programs face challenges in ensuring eligible clients are enrolled or renew their coverage. Participants will gain new strategies for creating effective enrollment partnerships as well as how to prepare staff, partners, and clients for Open Enrollment.
Resource (Conference Presentation) updated 09/14/2023
This session will focus on key findings and behavioral considerations for long-acting antiretroviral treatment (ART) HIV regimens, given the progress in research, development, and potential approval of these drugs. There will be a brief overview of the ATLAS and FLAIR studies, discussion of the medications, and an outline of the potential impact of the regimens on care delivery models, providers, patients, and payers if they are approved.
Resource (Conference Presentation) updated 09/14/2023